Opportunity Information: Apply for PA 06 386
Apply for PA 06 386
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Cancer Surveillance Using Health Claims based Data System (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.226 Research on Healthcare Costs, Quality and Outcomes 93.399 Cancer Control.
- This funding opportunity was created on Dec 5, 2008 and posted on May 4, 2006.
- Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Native American tribal governments (Federally recognized) Independent school districts For profit organizations other than small businesses City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled Additional Information on Eligibility for clarification) Special district governments County governments Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Public and State controlled institutions of higher education.
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith based or community based organizations can apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Cancer Surveillance Using Health Claims based Data System (R21) opportunity (PA 06 386) is a National Institutes of Health funding announcement led by the National Cancer Institute (NCI) in partnership with the Agency for Healthcare Research and Quality (AHRQ). It supports investigator-initiated exploratory and developmental research that uses health insurance claims data to strengthen cancer surveillance. In practical terms, the program is aimed at projects that test, refine, or validate ways to use claims data to better understand what cancer care looks like in the real world, including how care is delivered, whether it aligns with quality standards, what outcomes patients experience, and where disparities exist across populations and across the full continuum of cancer treatment.
A central emphasis of the FOA is methodological and validity-focused work. Applicants are encouraged to study how accurate, complete, and useful claims-based measures are for surveillance purposes, and to develop or improve analytic methods needed to use these data responsibly. This can include examining whether claims reliably identify cancer diagnoses, treatments, complications, recurrence signals, follow-up care, or end-of-life care; determining how well claims capture timing and sequencing of treatments; and exploring biases or limitations inherent in administrative billing data. The announcement also explicitly welcomes pilot studies and preliminary analyses that generate early evidence and feasibility results that can support larger, more definitive grant applications later.
The mechanism is an NIH Exploratory/Developmental Grant (R21), which is designed for early-stage, higher-risk, proof-of-concept work rather than large, fully powered projects. Awards are capped at a two-year project period and cannot be renewed under the R21 mechanism. Budget limits are set at up to $275,000 in total direct costs over the two years, with no more than $200,000 in direct costs allowed in any single year. Because projects can vary widely in scope, the actual award size and duration may differ by application, as long as they stay within the two-year limit. The number of awards is not predetermined and depends on the availability of funds and on how many high-quality, meritorious applications are received.
This R21 announcement runs in parallel with a companion FOA of the same scientific scope that uses the R01 mechanism (PA 06 385). The presence of both tracks signals an intent to support both exploratory work (R21) and larger, more comprehensive research programs (R01), giving investigators a path to start with pilot or methods development and then potentially scale up through an R01 if the preliminary work supports it.
Eligibility is broad and includes for-profit and nonprofit organizations, public or private institutions (such as universities, colleges, hospitals, and laboratories), units of state and local government, eligible federal institutions, and community-based or faith-based organizations. Tribal entities are also eligible, including federally recognized and other-than-federally recognized Indian/Native American Tribal Governments, as well as tribally designated organizations. Foreign institutions are eligible to apply as well. For project leadership, any qualified individual with the necessary expertise, resources, and institutional support may serve as the Project Director/Principal Investigator, and NIH notes that individuals from underrepresented racial and ethnic groups and individuals with disabilities are encouraged to apply. Applicants may submit more than one application as long as each proposal is scientifically distinct.
Administratively, this is a discretionary grant opportunity under NIH, associated with CFDA numbers 93.226 (Research on Healthcare Costs, Quality and Outcomes) and 93.399 (Cancer Control). It does not require cost sharing or matching. The posting date listed is May 4, 2006, and the FOA used multiple receipt dates (specific deadlines are referenced in the full announcement). The opportunity is archived as of June 1, 2009, but the description captures the program’s intent: advancing cancer surveillance by improving how health claims data are evaluated and used to measure cancer care patterns, quality, outcomes, and disparities.
Frequently Asked Questions (FAQs): Cancer Surveillance Using Health Claims-based Data System (R21) (PA 06 386)
What is this funding opportunity?
The Cancer Surveillance Using Health Claims based Data System (R21) opportunity (PA 06 386) is a National Institutes of Health (NIH) funding announcement led by the National Cancer Institute (NCI) in partnership with the Agency for Healthcare Research and Quality (AHRQ). It supports exploratory and developmental, investigator-initiated research focused on improving cancer surveillance using health insurance claims data.
What is the main goal of the program?
The goal is to strengthen cancer surveillance by testing, refining, validating, and improving ways to use health claims data to understand real-world cancer care. This includes examining how care is delivered, whether care aligns with quality standards, what outcomes patients experience, and where disparities exist across populations and across the full continuum of cancer treatment.
What types of projects does the FOA encourage?
The FOA emphasizes methodological and validity-focused projects. It encourages work that evaluates the accuracy, completeness, and usefulness of claims-based measures for cancer surveillance, and projects that develop or improve analytic methods needed to use claims data responsibly.
What kinds of cancer-related measures can be studied using claims data under this program?
Examples described in the announcement include assessing whether claims data can reliably identify cancer diagnoses, treatments, complications, recurrence signals, follow-up care, and end-of-life care. The FOA also highlights evaluating how well claims data capture the timing and sequencing of treatments.
Does the opportunity support pilot studies or preliminary analyses?
Yes. The announcement explicitly welcomes pilot studies and preliminary analyses that provide early evidence and feasibility findings that could support later applications for larger, more definitive projects.
What grant mechanism is used for this opportunity?
This opportunity uses the NIH Exploratory/Developmental Grant (R21) mechanism, which is intended for early-stage, proof-of-concept, and higher-risk projects rather than large, fully powered research studies.
What is the maximum project period?
The R21 awards are capped at a two-year project period.
Can an R21 award under this FOA be renewed?
No. The announcement states that awards cannot be renewed under the R21 mechanism.
What are the budget limits for this R21?
Budgets are limited to up to $275,000 in total direct costs over the two-year project period, with no more than $200,000 in direct costs permitted in any single year.
Can the actual award size or duration be shorter than the maximum?
Yes. The announcement notes that actual award size and duration may vary by application, as long as the project stays within the two-year limit and within the stated direct cost caps.
How many awards will be made?
The number of awards is not predetermined. It depends on the availability of funds and the number of high-quality, meritorious applications received.
Is there a companion funding opportunity for larger projects?
Yes. This R21 announcement runs in parallel with a companion FOA with the same scientific scope that uses the R01 mechanism (PA 06 385). The R21 track supports exploratory work, while the R01 track supports larger, more comprehensive research programs.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include for-profit and nonprofit organizations; public or private institutions such as universities, colleges, hospitals, and laboratories; units of state and local government; eligible federal institutions; and community-based or faith-based organizations.
Are Tribal entities eligible to apply?
Yes. Tribal eligibility includes federally recognized Indian/Native American Tribal Governments, other-than-federally recognized Tribal Governments, and tribally designated organizations.
Are foreign institutions eligible?
Yes. Foreign institutions are eligible to apply.
Who can serve as the Project Director/Principal Investigator (PD/PI)?
Any qualified individual with the necessary expertise, resources, and institutional support may serve as the PD/PI. The NIH also encourages individuals from underrepresented racial and ethnic groups and individuals with disabilities to apply.
Can an organization submit more than one application?
Yes. Applicants may submit more than one application, as long as each proposal is scientifically distinct.
Is cost sharing or matching required?
No. The announcement states that cost sharing or matching is not required.
What type of grant is this administratively?
This is described as a discretionary grant opportunity under NIH.
What CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA 93.226 (Research on Healthcare Costs, Quality and Outcomes) and CFDA 93.399 (Cancer Control).
When was this funding announcement posted?
The posting date listed is May 4, 2006.
Were there specific application deadlines?
Yes. The FOA used multiple receipt dates, with specific deadlines referenced in the full announcement.
Is this opportunity still active?
No. The opportunity is archived as of June 1, 2009.
What is the program trying to improve in real-world cancer surveillance?
Based on the description, the program aims to advance cancer surveillance by improving how claims data are evaluated and used to measure cancer care patterns, quality, outcomes, and disparities across populations and across the cancer care continuum.
What kinds of limitations or biases in claims data are relevant to this FOA?
The announcement highlights the importance of exploring biases or limitations inherent in administrative billing data and assessing how those limitations affect the validity and responsible use of claims-based surveillance measures.
Browse more opportunities from the same category: Education Health
Next opportunity: HIV Proteins and Their Cellular Binding Partners (R21/R33)
Previous opportunity: NIAID Clinical Trial Planning (R34) Grants
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 06 386
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 06 386) also looked into and applied for these:
| Funding Opportunity |
|---|
| Developmental Projects in Complementary Approaches to Cancer Care (R21) Apply for PA 06 400 Funding Number: PA 06 400 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Studies of Energy Balance and Cancer in Humans (R21) Apply for PA 06 405 Funding Number: PA 06 405 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Phased Innovation Research in Cancer Prognosis and Prediction (R21/R33) Apply for PA 06 434 Funding Number: PA 06 434 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Phase II Developmental Research in Cancer Prognosis and Prediction (R33) Apply for PA 06 435 Funding Number: PA 06 435 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Development of Frontal Cortex and Limbic System and their roles in Drug Abuse or Mental Health (R21) Apply for PA 06 445 Funding Number: PA 06 445 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Drug Abuse Dissertation Research Epidemiology, Prevention, Treatment, Services, and Women and Sex/Gender Differences (R36) Apply for PAR 06 476 Funding Number: PAR 06 476 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Behavioral and Integrative Treatment Development Program (R21) Apply for PA 06 487 Funding Number: PA 06 487 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Behavioral and Integrative Treatment Development Program (R03) Apply for PA 06 488 Funding Number: PA 06 488 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Health Services Research on Practice Improvement Utilizing Community Treatment Programs within the National Drug Abuse Clinical Trials Network (CTN) (R21) Apply for PA 06 496 Funding Number: PA 06 496 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Health Services Research on Practice Improvement Utilizing Community Treatment Programs within the National Drug Abuse Clinical Trials Network (CTN) (R03) Apply for PA 06 497 Funding Number: PA 06 497 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Exfoliated Cells and Circulating DNA in Cancer Detection and Diagnosis(R21) Apply for PA 06 499 Funding Number: PA 06 499 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Pathophysiology of Bisphosphonates associated Osteonecrosis of the Jaw (R03) Apply for PA 06 502 Funding Number: PA 06 502 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Pathophysiology of Bisphosphonates associated Osteonecrosis of the Jaw (R21) Apply for PA 06 501 Funding Number: PA 06 501 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| National Cancer Institute (NCI) Cancer Education and Career Development Program (R25) Apply for PAR 06 511 Funding Number: PAR 06 511 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) Apply for PA 06 461 Funding Number: PA 06 461 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R33) Apply for PA 06 462 Funding Number: PA 06 462 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (Phased Innovation Award R21/R33) Apply for PA 06 463 Funding Number: PA 06 463 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Dissemination and Implementation Research in Health (R03) Apply for PAR 06 520 Funding Number: PAR 06 520 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Dissemination and Implementation Research in Health (R21) Apply for PAR 06 521 Funding Number: PAR 06 521 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Translational Research for the Prevention and Control of Diabetes and Obesity (R18) Apply for PAR 06 532 Funding Number: PAR 06 532 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 06 386", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.